ORIENT BIO Inc.

Equities

A002630

KR7002630002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
526 ^KRW	-0.75%		+1.15%	-13.34%

2022	Pregen Inc. announced that it has received KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD.	CI
2022	Pregen Inc. announced that it expects to receive KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD. and other investors	CI

ORIENT BIO Inc. announced that it has received KRW 4.64699064 billion in funding

December 23, 2019

ORIENT BIO Inc. (KOSE:A002630) announced a private placement of 798,452 common shares at a price of KRW 5,820 per shares for gross proceeds of KRW 4,646,990,640 on December 24, 2019. The transaction has been approved by board of director of the company.

Latest news about ORIENT BIO Inc.

Pregen Inc. announced that it has received KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD.	15/12/22	CI
Pregen Inc. announced that it expects to receive KRW 1.7 billion in funding from Orient Co.,Ltd, ORIENT BIO Inc., ORIENT WATCH CO.,LTD. and other investors	30/11/22	CI
Orient Electronics Co.,Ltd. announced that it has received KRW 3.049998525 billion in funding from Orient Precision Industries Inc, ORIENT BIO Inc.	09/08/22	CI
Orient Electronics Co.,Ltd. announced that it expects to receive KRW 3.049998525 billion in funding from Orient Precision Industries Inc, ORIENT BIO Inc.	19/07/22	CI
ORIENT BIO Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Inotiv, Inc. acquired Orient BioResource Center, Inc. from ORIENT BIO Inc. for $51.3 million.	26/01/22	CI
ORIENT BIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	15/11/21	CI
ORIENT BIO Inc.(KOSE:A002630) dropped from S&P Global BMI Index	21/09/20	CI
ORIENT BIO Inc. announced that it has received KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.	04/08/20	CI
ORIENT BIO Inc. announced that it expects to receive KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.	27/07/20	CI
ORIENT BIO Inc. agreed to acquire an additional 29.74% stake in Orient Electronics Co.,Ltd. for KRW 6.7 billion.	27/07/20	CI
ORIENT BIO Inc. announced that it has received KRW 4.64699064 billion in funding	23/12/19	CI
Orient Precision Industries Inc. cancelled the acquisition of an additional 27.6% stake in Orient Electronics Co.,Ltd from ORIENT BIO Inc..	27/03/18	CI
ORIENT BIO Inc. announced that it has received KRW 30 billion in funding	15/05/17	CI
Orient Bio, Inc. to Raise USD 26.4 Million in Private Placement of Bonds Due 2021	16/04/17	CI
ORIENT BIO Inc. announced that it expects to receive KRW 30 billion in funding	13/04/17	CI
Orient Precision Industries Inc. announced that it has received KRW 5 billion in funding from ORIENT BIO Inc., Mdas Inc.	04/04/17	CI
Orient Precision Industries Inc. announced that it expects to receive KRW 5 billion in funding from ORIENT BIO Inc., Mdas Inc.	03/04/17	CI
Orient Precision Industries Inc. agreed to acquire an additional 27.6% stake in Orient Electronics Co.,Ltd from ORIENT BIO Inc. for KRW 5 billion.	27/03/17	CI
ORIENT BIO Inc. announced that it has received KRW 10 billion in funding from Eugene investment & Securities Co., Ltd., Investment Arm	02/06/16	CI
ORIENT BIO Inc. announced that it expects to receive KRW 10 billion in funding from Eugene investment & Securities Co., Ltd., Investment Arm	31/05/16	CI
ORIENT BIO Inc. announced that it has received KRW 7 billion in funding from Eugene investment & Securities Co., Ltd., Investment Arm	15/10/15	CI
ORIENT BIO Inc. announced that it expects to receive KRW 7 billion in funding from Eugene investment & Securities Co., Ltd., Investment Arm	13/10/15	CI
ORIENT BIO Inc.(KOSE:A002630) added to S&P Global BMI Index	21/09/15	CI
Orientbio, Inc. cancelled the acquisition of an additional 7.19% stake in Orient Precision Industries Inc.	21/11/12	CI

Chart ORIENT BIO Inc.

Duration

Period

More charts

Company Profile

ORIENT BIO Inc. is a Korea-based company engaged in the biotechnology area. The Company produces and supplies laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free (SPF) rabbits, beagles and others. It also provides contract research organization (CRO) services, including CRO safety assessment and CRO new drug development services; medical and library equipment, such as barrier systems, and support services such as rodent surgery services, laboratory diagnostics services, transgenic services, genetic testing services and other services. In addition, along with its subsidiaries, the Company provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ORIENT BIO INC.	-13.34%	45.61M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	111B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	21.93B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-7.66%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-10.09%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.45B

Bio Therapeutic Drugs